1AI 0.00% 0.7¢ algorae pharmaceuticals limited

Ann: Results of LCT Parkinsons trial require further analysis, page-109

  1. 54 Posts.
    whytee, you mention responsiveness to l-dopa. during the cc it was mentioned that all the patients in the phase1 trial had been approved for DBS and 1 criteria for that is good l-dopa responsiveness. it was stated all patients in phase2 had been diagnosed at least 5 years ago, under 65 and were heading towards getting a DBS eventually which implies L-DOPA responsiveness, i'm sure they must have measured them ON and OFF in the UPDRS motor test to make sure the responded well to l-dopa. you take the test 10hrs after your last meds, then take your meds and re-test 90minutes later. i assume they tried to select patients that didn't have atypical parkinson's. if you go to a parkinson's support group you'll quickly see no 2 pd'ers are alike.
 
watchlist Created with Sketch. Add 1AI (ASX) to my watchlist
(20min delay)
Last
0.7¢
Change
0.000(0.00%)
Mkt cap ! $11.81M
Open High Low Value Volume
0.7¢ 0.7¢ 0.7¢ $4.495K 642.1K

Buyers (Bids)

No. Vol. Price($)
8 4953269 0.7¢
 

Sellers (Offers)

Price($) Vol. No.
0.8¢ 954858 11
View Market Depth
Last trade - 16.10pm 13/09/2024 (20 minute delay) ?
1AI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.